Insights on Health Care
1339 total results. Page 2 of 54.
On July 7, the DC Council passed the Fiscal Year 2027 Budget Support Act (BSA) of 2026, the annual legislative vehicle through which the Council enacts the legal and policy changes required to carry out the District’s budget.
Every July, the Centers for Medicare & Medicaid Services (CMS) publishes two proposed rules, the Physician Fee Schedule (PFS) proposed rule and the Hospital Outpatient Prospective Payment System (HOPPS) proposed rule, that set Medicare reimbursement and shape the administration of the Medicare Part B program for the upcoming calendar year.
In the last year, the Massachusetts Attorney General (AG) adopted two sets of sweeping consumer protection regulations directly impacting assisted living residence (ALR) operators. These regulations significantly expand ALR obligations regarding disclosures, billing, tenancy protections, resident rights, and pricing transparency.
Beginning July 1, the State of Washington will require all assisted living facilities that operate memory care units — or market themselves as providing specialized dementia care — to obtain a new state certification or face state Consumer Protection Act liability. Here is what current operators and prospective applicants need to know.
On June 23, 2026, ArentFox Schiff hosted the HGPII Annual Best Practices Forum, an annual ethics and best business practices training session. The annual forum brings together executives from Group Purchasing Organizations (GPOs) across the country, providing a dynamic platform for evaluating best practices and exploring the latest innovations in health care supply chain management.
Pat Naples was quoted on how data analytics and fraud-detection software was used by the US Department of Justice (DOJ) in one of the largest coordinated health care fraud enforcement actions to date.
ArentFox Schiff is pleased to announce that 23 practices and 81 attorneys have been recognized by The Legal 500 United States 2026 guide.
On June 2, the US Food and Drug Administration (FDA) released a new draft guidance called “Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing.”
On June 8, the California State Senate adopted Senate Resolution (SR) 104, a measure expressing support for targeting the biological mechanisms of aging as a strategy to prevent and delay chronic disease.
The 2027 DC budget proposes substantial investments in health care access, behavioral health services, and public health infrastructure across the District of Columbia. Nearly four in 10 DC residents depend on Medicaid, the Basic Health Plan, or the locally funded Alliance program for coverage.
On June 4, the US Supreme Court issued a unanimous decision authored by Justice Ketanji Brown Jackson in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24–889, delivering a significant win for generic pharmaceutical manufacturers seeking US Food and Drug Administration (FDA) approval for drugs with multiple indications.
The US Departments of Treasury, Labor, and Health and Human Services have issued a sweeping final rule (CMS-9897-F) implementing significant changes to the Federal Independent Dispute Resolution (IDR) process established under the No Surprises Act (NSA).
ArentFox Schiff is pleased to announce that 68 attorneys were recognized as leaders in their field and 25 practices spanning the firm’s litigation, regulatory, and transactional capabilities, as well as key industries, were ranked among the best in the country in the 2026 edition of Chambers USA: America’s Leading Lawyers for Business.
Forget science fiction — the race to connect computers directly to the human brain is already underway, and it is accelerating. In recent months, neurotechnology companies have expanded human clinical trials and attracted substantial investment.
In a 2-1 decision authored by Judge Timothy B. Dyk, the Federal Circuit reversed a jury verdict awarding Insulet Corporation over $59 million in compensatory and exemplary damages for trade secret misappropriation under the Defend Trade Secrets Act (DTSA).
The U.S. Food and Drug Administration is building a new regulatory framework for artificial intelligence and machine learning in medical software. This article argues that the FDA’s evolving approach extends beyond a compliance issue for technology developers; it is a market-shaping force that will change how healthcare providers buy, deploy, and govern AI-enabled tools.
ArentFox Schiff’s Gayland Hethcoat on navigating the line between wellness and medical devices in the longevity era.
On April 29, the US Food and Drug Administration (FDA) published a Request for Information (RFI) seeking public comment on a proposed pilot program to test the use of artificial intelligence (AI) in early-stage clinical trials for drugs and biologics. Comments are due June 29.